Cargando…
Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
In hepatocellular carcinoma (HCC), the clinical significance of soluble immune checkpoint protein levels as predictors of patient outcomes or therapeutic responses has yet to be defined. This study profiled the baseline levels of sixteen soluble checkpoint proteins and their changes following sorafe...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042216/ https://www.ncbi.nlm.nih.gov/pubmed/32099055 http://dx.doi.org/10.1038/s41598-020-60440-5 |
_version_ | 1783501265778507776 |
---|---|
author | Dong, Minh Phuong Enomoto, Masaru Thuy, Le Thi Thanh Hai, Hoang Hieu, Vu Ngoc Hoang, Dinh Viet Iida-Ueno, Ayako Odagiri, Naoshi Amano-Teranishi, Yuga Hagihara, Atsushi Fujii, Hideki Uchida-Kobayashi, Sawako Tamori, Akihiro Kawada, Norifumi |
author_facet | Dong, Minh Phuong Enomoto, Masaru Thuy, Le Thi Thanh Hai, Hoang Hieu, Vu Ngoc Hoang, Dinh Viet Iida-Ueno, Ayako Odagiri, Naoshi Amano-Teranishi, Yuga Hagihara, Atsushi Fujii, Hideki Uchida-Kobayashi, Sawako Tamori, Akihiro Kawada, Norifumi |
author_sort | Dong, Minh Phuong |
collection | PubMed |
description | In hepatocellular carcinoma (HCC), the clinical significance of soluble immune checkpoint protein levels as predictors of patient outcomes or therapeutic responses has yet to be defined. This study profiled the baseline levels of sixteen soluble checkpoint proteins and their changes following sorafenib treatment for HCC. Plasma samples were obtained from 53 patients with advanced HCC at baseline, week 1, 2 and 4 of sorafenib treatment and tested the concentrations of 16 soluble checkpoint proteins using multiplexed fluorescent bead-based immunoassays. Multivariate analysis showed high sBTLA levels at baseline were an independent predictor of poor overall survival (p = 0.038). BTLA was highly expressed in T cells and macrophages in peritumoral areas. At week 2, sCD27 levels were decreased compared to baseline. By contrast, the concentrations of most inhibitory proteins, including sBTLA, sLAG-3, sCTLA-4, sPD-1, sCD80, sCD86 and sPD-L1, had significantly increased. The fold-changes of soluble checkpoint receptors and their ligands, including sCTLA-4 with sCD80/sCD86, sPD-1 with sPD-L1; and the fold-changes of sCTLA-4 with sBTLA or sPD-1 were positively correlated. sBTLA may be a good biomarker for predicting overall survival in HCC patients. Sorafenib treatment in patients with advanced HCC revealed dynamic changes of soluble checkpoint protein levels. |
format | Online Article Text |
id | pubmed-7042216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70422162020-03-03 Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma Dong, Minh Phuong Enomoto, Masaru Thuy, Le Thi Thanh Hai, Hoang Hieu, Vu Ngoc Hoang, Dinh Viet Iida-Ueno, Ayako Odagiri, Naoshi Amano-Teranishi, Yuga Hagihara, Atsushi Fujii, Hideki Uchida-Kobayashi, Sawako Tamori, Akihiro Kawada, Norifumi Sci Rep Article In hepatocellular carcinoma (HCC), the clinical significance of soluble immune checkpoint protein levels as predictors of patient outcomes or therapeutic responses has yet to be defined. This study profiled the baseline levels of sixteen soluble checkpoint proteins and their changes following sorafenib treatment for HCC. Plasma samples were obtained from 53 patients with advanced HCC at baseline, week 1, 2 and 4 of sorafenib treatment and tested the concentrations of 16 soluble checkpoint proteins using multiplexed fluorescent bead-based immunoassays. Multivariate analysis showed high sBTLA levels at baseline were an independent predictor of poor overall survival (p = 0.038). BTLA was highly expressed in T cells and macrophages in peritumoral areas. At week 2, sCD27 levels were decreased compared to baseline. By contrast, the concentrations of most inhibitory proteins, including sBTLA, sLAG-3, sCTLA-4, sPD-1, sCD80, sCD86 and sPD-L1, had significantly increased. The fold-changes of soluble checkpoint receptors and their ligands, including sCTLA-4 with sCD80/sCD86, sPD-1 with sPD-L1; and the fold-changes of sCTLA-4 with sBTLA or sPD-1 were positively correlated. sBTLA may be a good biomarker for predicting overall survival in HCC patients. Sorafenib treatment in patients with advanced HCC revealed dynamic changes of soluble checkpoint protein levels. Nature Publishing Group UK 2020-02-25 /pmc/articles/PMC7042216/ /pubmed/32099055 http://dx.doi.org/10.1038/s41598-020-60440-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Dong, Minh Phuong Enomoto, Masaru Thuy, Le Thi Thanh Hai, Hoang Hieu, Vu Ngoc Hoang, Dinh Viet Iida-Ueno, Ayako Odagiri, Naoshi Amano-Teranishi, Yuga Hagihara, Atsushi Fujii, Hideki Uchida-Kobayashi, Sawako Tamori, Akihiro Kawada, Norifumi Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
title | Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
title_full | Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
title_fullStr | Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
title_full_unstemmed | Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
title_short | Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
title_sort | clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042216/ https://www.ncbi.nlm.nih.gov/pubmed/32099055 http://dx.doi.org/10.1038/s41598-020-60440-5 |
work_keys_str_mv | AT dongminhphuong clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT enomotomasaru clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT thuylethithanh clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT haihoang clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT hieuvungoc clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT hoangdinhviet clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT iidauenoayako clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT odagirinaoshi clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT amanoteranishiyuga clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT hagiharaatsushi clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT fujiihideki clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT uchidakobayashisawako clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT tamoriakihiro clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma AT kawadanorifumi clinicalsignificanceofcirculatingsolubleimmunecheckpointproteinsinsorafenibtreatedpatientswithadvancedhepatocellularcarcinoma |